Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sargramostim after Allogeneic BMT for CML
NCT00002778Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 1995
- Primary completion
- Feb 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim in chronic myeloid leukemia (CML), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Reduction of Leukemic Relapse at 2 years. Started Feb 1995; status: terminated.
02
Drugs
sargramostim
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00002778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002778.